3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioblastoma
3
Brain Neoplasms
2
Neoplasms
1
Gliosarcoma
1
Interventions
Temozolomide
53
Bevacizumab
33
Radiotherapy
27
Radiation
12
Erlotinib Hydrochloride
12
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Irinotecan
6
Vorinostat
5
Sorafenib
5
Sirolimus
5
temsirolimus
4
Magnetic Resonance Spectroscopy
4
Immunoglobulin G
4
Disulfides
4
Carmustine
4
veliparib
3
plerixafor
3
carmustine, poliferprosan 20 drug combination
3
Radiosurgery
3
Everolimus
3
Dasatinib
3
Bortezomib
3
vandetanib
2
tandutinib
2
sargramostim
2
poly ICLC
2
pembrolizumab
2
pazopanib
2
ferric pyrophosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gliosarcoma
×
depatuxizumab mafodotin
×
Clear all
NCT02573324
2023-05-11
Intellance1
AbbVie
Phase 3
Completed
691 enrolled
28 charts